



(51) International Patent Classification:

A61K 31/403 (2006.01) A61P 29/00 (2006.01)  
A61P 25/02 (2006.01) C07D 209/52 (2006.01)  
A61P 25/04 (2006.01)

(21) International Application Number:

PCT/US2024/018624

(22) International Filing Date:

06 March 2024 (06.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/489,563 10 March 2023 (10.03.2023) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly  
Corporate Address, Indianapolis, Indiana 46285 (US).

(72) Inventors: **KIELBASA, William Brian**; c/o Eli Lilly and  
Company, Lilly Corporate Center, Indianapolis, Indiana  
46285 (US). **MONK, Scott Alan**; c/o Eli Lilly and Com-  
pany, Lilly Corporate Center, Indianapolis, Indiana 46285  
(US). **PEARLMAN, Eric Michael**; c/o Eli Lilly and Com-  
pany, Lilly Corporate Center, Indianapolis, Indiana 46285  
(US). **REMICK, David Michael**; c/o Eli Lilly and Com-  
pany, Lilly Corporate Center, Indianapolis, Indiana 46285  
(US). **RIZZO, John Robert**; c/o Eli Lilly and Company,  
Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(74) Agent: **McCRARY, Parker** et al.; c/o Eli Lilly and Com-  
pany, Lilly Corporate Center, Indianapolis, Indiana 46285  
(US).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR THE PREPARATION AND DOSE REGIMENS FOR USE OF SSTR4 AGONISTS AND SALTS THEREOF




FIG. 1

(57) Abstract: Method for preparing SSTR4 agonist compounds. Method for preparing SSTR4 agonist compounds through a diastereomerically selective cyclization reaction without the need for a separate epimerization step. Novel intermediates for preparing SSTR4 agonist compounds. Dose regimens for the treatment of pain and/or neuropathic pain, such as diabetic peripheral neuropathy, central neuropathy, or mixed neuropathy.

[Continued on next page]

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*